Zhang Zi-Lai, Wang Jin-Hui, Liu Xin-Yuan
Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, the Chinese Academy of Sciences, Shanghai 200031, China.
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2003 Oct;35(10):873-80.
Neovascularization is a prerequisite for progressive growth of most tumors and their metastases. Therefore, inhibition of angiogenesis could be one of the most promising strategies that might lead to the development of novel anticancer therapy. New blood vessels forming in tumors can be avoided by interfering the process of angiogenesis through suppressing the proangiogenic signal or augmenting the antiangiogenic factors. Concentrated efforts in this area have lead to the discovery of many proangiogenic factors as well as their inhibitors, and antiangiogenic factors. For the established tumor vasculature, tumor vasculature-targeted delivery of antiangiogenic substances and endothelial cell vaccines has been explored. Although some antiangiogenic drugs are currently in clinical development, for future reason, more efficient therapeutic methods, including antiangiogenic gene therapy strategy, targeted drug delivery system, and the combination of antiangiogenic agents with immunotherapy, chemotherapy or radiotherapy are being explored. With the development of tumor model assessment system, clinical use of the above antiangiogenic tumor therapy methods could be achieved.
新生血管形成是大多数肿瘤及其转移灶进行性生长的前提条件。因此，抑制血管生成可能是最有前景的策略之一，有望带来新型抗癌疗法的发展。通过抑制促血管生成信号或增强抗血管生成因子来干扰血管生成过程，可以避免肿瘤中形成新的血管。在这一领域的集中研究已导致发现了许多促血管生成因子及其抑制剂以及抗血管生成因子。对于已建立的肿瘤血管系统，已探索了肿瘤血管靶向递送抗血管生成物质和内皮细胞疫苗。尽管目前一些抗血管生成药物正处于临床开发阶段，但出于未来的考虑，正在探索更有效的治疗方法，包括抗血管生成基因治疗策略、靶向药物递送系统以及抗血管生成药物与免疫疗法、化疗或放疗的联合应用。随着肿瘤模型评估系统的发展，上述抗血管生成肿瘤治疗方法有望实现临床应用。
